FORECAST · GRANT
Studies Addressing Rare Neurodegenerative Diseases including ALS
- Expected deadline
- Not stated
- Who can apply
- Anyone eligible under the notice (unrestricted)
- Award range
- Not stated
- Expected awards
- 10
- Total program funding
- Not stated
- Your own money required
- No cost sharing or matching required
- Opportunity number
- FOR-FD-25-006
- Posted
- Aug 14, 2024
- Assistance listing
- 93.103
What it funds
The purpose of this funding opportunity announcement (FOA) is to support studies that advance medical product development of interventions intended to prevent, diagnose, mitigate, treat, or cure ALS and other rare neurodegenerative diseases in adults and children. Through the support of these studies, FDA expects to address critical knowledge gaps, exert a significant impact on rare neurodegenerative diseases, and to inform current or future product development.
Open the official notice on Grants.gov ↗What to do next
- This is a forecast: the agency expects to post the full notice later. Open it on Grants.gov and subscribe there to be told when it posts.
- Get your SAM.gov registration ("all awards") and Grants.gov account active now; both take time.
- Use the forecast's award range and eligibility to decide whether to prepare.
- Watch for the notice; the dates here are estimates and can change.
New to this? Applying for a federal grant, step by step · Register to apply · How to read the notice · Write the narrative · Build the budget · Agency contact: terrin.brown@fda.hhs.gov
From Grants.gov's official daily extract of Oct 25, 2026. The notice on Grants.gov and its attachments are what count. UX Contract is independent and not a government website.